Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Paz-Ares, L.; Chen, Y.; Reinmuth, N.; Hotta, K.; Trukhin, D.; Statsenko, G.; Hochmair, M.; ÖZGÜROĞLU, MUSTAFA; Ji, J.; Garassino, M.; Voitko, O.; Poltoratskiy, A.; Musso, E.; Havel, L.; Bondarenko, I; Losonczy, G.; Conev, N.; Mann, H.; Dalvi, T.; Jiang, H.; Goldman, J.

doi:10.1016/j.esmoop.2022.100408

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., ...Daha Fazla

ESMO OPEN, cilt.7, sa.2, 2022 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 7 Sayı: 2
Basım Tarihi: 2022
Doi Numarası: 10.1016/j.esmoop.2022.100408
Dergi Adı: ESMO OPEN
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
Anahtar Kelimeler: durvalumab, tremelimumab, extensive-stage SCLC, CASPIAN, overall survival, EXPRESSION, OUTCOMES
İstanbul Üniversitesi Adresli: Hayır

Özet

Background: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus tremelimumab plus EP numerically improved OS versus EP, but did not reach statistical significance. Here we report updated OS in censored patients after median follow-up of >3 years.